Good managers set the tone for the whole team, encouraging positive behavior from everyone around them. In the November 5 Nature, scientists introduce a subtype of microglia that appears to do just ...
Hypertension heightens the risk of Alzheimer’s disease, but exactly how is not understood. In a bioRxiv preprint posted September 19, scientists led by Costantino Iadecola at Weill Cornell Medical ...
This knock-in (KI) mouse model was generated by introducing a D427V point mutation into exon 10 of the mouse Gba1 (glucosidase, beta, acid 1) gene, which corresponds to the human D409V mutation (The ...
This APP transgenic overexpresses mutant human APP under the control of the Thy-1.2 promoter, driving neuronal expression. The transgene carries two mutations associated with familial Alzheimer’s ...
901 E. Willeta Street Phoenix, AZ85006 United States Visit Website Contact: Eric Reiman, M.D. Phone: 602-839-6999 Fax: 602-239-6253 E-mail: eric.reiman@bannerhealth ...
Building 114, Suite 2011 16th Street Charlestown, MA02129 United States Visit Website Contact: Bradley T. Human, M.D., Ph.D. Phone: (617) 726-3987 E-mail: [email protected] Brain Banks Home ...
In September 2016, the Cocoa Supplement and Multivitamin Outcomes Study of Cognition (COSMOS-Mind) began enrolling 2,262 people 65 or older without dementia to evaluate the effect of three years of ...
In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...
The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.
In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...
If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...
Earlier this year, a high-profile Science paper caused a stir with its claim that the brain has a fourth, previously unrecognized, meningeal membrane. Dubbed SLYM and containing Prox1+ cells, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results